Canada markets closed

Provectus Biopharmaceuticals, Inc. (PVCT)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1930+0.0017 (+0.91%)
At close: 03:59PM EDT
Currency in USD

Valuation Measures4

Market Cap (intraday) 80.99M
Enterprise Value 83.96M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)134.15
Price/Book (mrq)N/A
Enterprise Value/Revenue N/A
Enterprise Value/EBITDA -29.19

Trading Information

Stock Price History

Beta (5Y Monthly) 0.70
52-Week Change 337.41%
S&P500 52-Week Change 322.38%
52 Week High 30.2250
52 Week Low 30.0560
50-Day Moving Average 30.1820
200-Day Moving Average 30.1248

Share Statistics

Avg Vol (3 month) 3327.23k
Avg Vol (10 day) 3121.86k
Shares Outstanding 5419.52M
Implied Shares Outstanding 6419.52M
Float 8385.53M
% Held by Insiders 19.42%
% Held by Institutions 10.05%
Shares Short (Sept 30, 2016) 41.82M
Short Ratio (Sept 30, 2016) 40.47
Short % of Float (Sept 30, 2016) 40.78%
Short % of Shares Outstanding (Sept 30, 2016) 40.75%
Shares Short (prior month Aug 31, 2016) 42.86M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 21:300
Last Split Date 3Apr 11, 2002

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2023
Most Recent Quarter (mrq)Dec 31, 2023

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-179.67%

Management Effectiveness

Return on Assets (ttm)-89.58%
Return on Equity (ttm)N/A

Income Statement

Revenue (ttm)557.71k
Revenue Per Share (ttm)0.00
Quarterly Revenue Growth (yoy)-26.50%
Gross Profit (ttm)N/A
EBITDA -2.49M
Net Income Avi to Common (ttm)-3.1M
Diluted EPS (ttm)-0.0100
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)76.58k
Total Cash Per Share (mrq)0
Total Debt (mrq)3.03M
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)0.15
Book Value Per Share (mrq)-0.02

Cash Flow Statement

Operating Cash Flow (ttm)-2.57M
Levered Free Cash Flow (ttm)-1.16M